US Senate Passes Eliminate Colorectal Cancer Act

Publication
Article
OncologyONCOLOGY Vol 16 No 10
Volume 16
Issue 10

The US Senate Health, Education, Labor, and Pensions Committee has passed the Eliminate Colorectal Cancer Act (S.710), legislation introduced by Sen. Jesse Helms (R-NC) and Sen. Edward M. Kennedy (D-Mass). The bill, with the companion

The US Senate Health, Education, Labor, and Pensions Committeehas passed the Eliminate Colorectal Cancer Act (S.710), legislation introducedby Sen. Jesse Helms (R-NC) and Sen. Edward M. Kennedy (D-Mass). The bill, withthe companion HR 1520 being mulled by the US House of Representatives, wouldrequire all private health insurance plans to cover colon cancer screeningaccording to scientific guidelines for patients age 50 and over and for othersat high risk of developing the disease.

In a statement, the American Cancer Society noted, "It isup to Congress to ensure that the barriers to life-saving colon cancerscreenings tests are removed. . . The bottom line is that this Act can helpprolong lives and prevent the pain and anguish cancer causes."

Related Videos
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.